Market revenue in 2023 | USD 579.6 million |
Market revenue in 2030 | USD 916.9 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Synthetic |
Fastest growing segment | Biotech |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Synthetic, Biotech |
Key market players worldwide | Basf SE, CordenPharma, Bristol-Myers Squibb Co, Pfizer Inc, Boehringer Ingelheim Pharma, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Albany Molecular Research, Sanofi SA, Lonza Group Ltd, Cipla Ltd DR, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG ADR, Roche Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to high potency active pharmaceutical ingredients market will help companies and investors design strategic landscapes.
Synthetic was the largest segment with a revenue share of 73.69% in 2023. Horizon Databook has segmented the Spain high potency active pharmaceutical ingredients market based on synthetic, biotech covering the revenue growth of each sub-segment from 2018 to 2030.
Elderly population is more susceptible to conditions such as cancer, diabetes, obesity, and cardiovascular diseases, leading to greater demand on the healthcare infrastructure. However, presence of developed healthcare infrastructure, favorable reimbursement policies, and high demand for oncology drugs are anticipated to fuel the market growth.
In April 2020, AGC Chemicals announced that it is increasing the capacity of its synthetic API production. It also manufactures biopharmaceuticals and biologics. International investments in Spain’s biotechnology ecosystem are also growing. For instance, in 2015, Sanifit received over EUR 36 million international investment.
Even during the COVID-19 pandemic, Spain pharmaceutical sector is getting high investments, which is anticipated to positively influence high potency active pharmaceutical ingredients market. The number of new cases of cancer is estimated to surpass 270,363 annually. Thus, rising number of cancer cases is expected to drive the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain high potency active pharmaceutical ingredients market , including forecasts for subscribers. This country databook contains high-level insights into Spain high potency active pharmaceutical ingredients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account